Intensified Neoadjuvant Therapy Improves Outcomes in Very High-Risk Prostate Cancer
Investigators compared ADT plus abiraterone or docetaxel with ADT alone.
Adding Ipilimumab to Nivolumab Doesn’t Provide Meaningful Benefit, Researchers Say
Adding ipilimumab to treatment with nivolumab does not provide a clinically meaningful benefit in patients with certain cancers, a meta-analysis suggests.
Cancer Screenings, Early Diagnosis Significantly Affected During First Year of Pandemic
An evaluation of data from 2018-2019 and 2020 show the effects of pandemic management on cancer screening, diagnosis, and care.
Nighttime Aromatherapy Improves Well-Being in Hospitalized Patients With Cancer
A quasi-experimental pilot trial sought to determine if aromatherapy could improve sleep, well-being, and other outcomes in hospitalized patients with cancer.
Screening Confers “Small” Survival Benefit in High-Grade Serous Ovarian Cancer
Screening can lead to earlier diagnosis of high-grade serous ovarian cancer, but this does not translate to a substantial improvement in survival, according to researchers.
Gut Microbiome May Aid Diagnosis, Prognostication in Metastatic NSCLC
Researchers have found evidence to suggest that patients with metastatic non-small cell lung cancer have unique gut microbiomes.
Atezolizumab Can Induce Response in Alveolar Soft Part Sarcoma
Anti-PD-L1 agent induces sustained responses seen in about one-third of patients with advanced alveolar soft part sarcoma.
Geriatric Assessments Predict Malnutrition Risks in Older Patients With Breast Cancer
Malnutrition was associated with cancer stage and geriatric symptoms in older women with breast cancer, according to a recent study.
Global Incidence of Early-Onset Cancers Rose 80% From 1990 to 2019
New data suggest that, from 1990 to 2019, the global incidence of early-onset cancer increased by nearly 80%, and the rate of early-onset cancer deaths increased by nearly 30%.
Neoadjuvant Camrelizumab Combos Demonstrate Efficacy in Stage II-III NSCLC
Neoadjuvant camrelizumab in combination with either platinum-doublet chemotherapy or apatinib has demonstrated efficacy in stage II-III NSCLC, according to researchers.
- Loading...
